Skip to main content

Enrique Grande

Contact

address:

MD Anderson Cancer Center Madrid, Madrid, Spain

Dr Enrique Grande, MD, PhD, Msc, is the Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Cancer Center Madrid. Dr Grande is focus on the research on Genitourinary and Endocrine tumors and takes active collaboration in the development of the Translational Research and Early Drug Development Unit. Dr Grande was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism, and he holds a master’s degree in the molecular biology of cancer from the Spanish National Cancer Research Centre (CNIO). Published author of more than 200 manuscripts in peer-reviewed journals, Dr Grande is also the founder of the Spanish Group of Research on Orphan and Uncommon Tumours (GETHI).

Dr Grande is editor of several international journals and has participated in the most recent trials in the field of bladder cancer that led to the approval of the new drugs we have now available and chairs the steering committee of the IMVIGOR 130 trial.

Disclosures

  • Advisory boards, meetings and/or lectures: Pfizer, BMS, Ipsen, Roche, Eisai, Eusa Pharma, MSD, Sanofi, AAA, Novartis, Pierre Fabre, Lexicon, and  Celgene
  • Unrestricted research grants: Pfizer, Astra Zeneca
print
PRINT

Latest contributions from Enrique Grande

Available treatment options and emerging clinical trial data for mUC

19-01-2021 | Urothelial cancer | Video

Available treatment options and emerging clinical trial data for mUC

Enrique Grande and Matthew Galsky discuss treatment options for patients with mUC and explain how new data may affect clinical practice in the future (16:15).

This activity is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany.

Enrique Grande

30-09-2019 | Urothelial cancer | Video | Article

Researcher comment: IMvigor130 trial of atezolizumab in advanced urothelial cancer

Enrique Grande tells us why the IMvigor130 data, although very promising, are not quite ready for translation to the clinic yet (1:43).